FDA warns Xiamen Wally Bath over current good manufacturing practice failures for over-the-counter hand sanitizer, including raw material and release testing gaps.
What happened
FDA reviewed records Xiamen Wally Bath submitted after FDA's June 15, July 5, and July 10, 2022 requests under section 704(a)(4) of the FD&C Act; this was a records review, not an inspection. FDA found significant current good manufacturing practice (CGMP) violations: no demonstrated identity testing of incoming raw materials, reliance on supplier certificates of analysis, no testing of all ethanol lots for methanol or a methanol limit, inadequate finished-product release testing, and insufficient stability data.
What FDA found
The firm relied on supplier certificates of analysis instead of testing each incoming raw material for identity and did not test all ethanol lots for methanol or set a methanol limit.
21 CFR 211.84(d)(1)The firm did not show full laboratory testing of each finished OTC drug batch for identity, strength, and impurities before U.S. release.
21 CFR 211.165(a)The firm lacked adequate stability data: only 13-week data supported the assigned expiry, and the data did not include identity, strength, or microbiological testing.
21 CFR 211.166(a)
What FDA wants
FDA tells the firm to correct the violations promptly and respond in writing within 15 working days with corrective actions or a delay explanation and completion schedule. FDA also placed the firm on Import Alert 66-40 and may withhold approvals or refuse admission.
Who should pay attention
- brands that buy OTC drugs or hand sanitizer from this manufacturer
- U.S. distributors and importers of ROADPRO Hand Sanitizer
- contract manufacturers and suppliers that rely on certificates of analysis for raw materials
This is a summary. Read the original letter on fda.gov.